

1

UNITED STATE EPARTMENT OF COMMERCE United States Patent and Trad mark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		AT	TORNEY DOCKET NO.
09/775,750	02/02/01	JONGSMA		В	AHP-98248 P1
-		HM12/1002	コ	E	KAMINER
JOHN F. LEVIS				FOLEY,S	
AMERICAN H	OME PRODUCT	S CORPORATION		ART UNIT	PAPER NUMBER
PATENT LAW ONE CAMPUS PARSIPPANY		•		1648	10/02/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

. Office Action Summary		Application No.	Applicant(s)				
		09/775,750	JONGSMA ET AL.				
		Examiner	Art Unit				
		Shanon A. Foley	1648				
The MAILING DATE of this communication app ars on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
_	munication(s) filed on <i>02 J</i>	uly 2001 .					
2a)⊠ This action is FINA		is action is non-final.					
3) Since this application	-						
Disposition of Claims							
4) Claim(s) 1-22 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1-22</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) dispected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
 Certified copies of the priority documents have been received. 							
2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
Notice of References Cited (PT 2) Notice of Draftsperson's Patent 3) Information Disclosure Statement	Drawing Review (PTO-948)	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)				

Art Unit: 1648

DETAILED ACTION

Response to Amendment

The amendment filed 7/10/01 is objected to under 35 U.S.C. 132 because it introduces new matter into the disclosure. 35 U.S.C. 132 states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: "wherein the vaccine is not serially passaged through tissue culture" and "[a] non-serially passaged". Applicant states that support for the amendment is found on in example 1 bridging pages 5 and 6. This negative limitation appearing in amended claims 1, 13, and 15, and new claim 19 cannot be found in the original disclosure. The courts have found that any negative limitation or exclusionary proviso must have basis in the original disclosure. The mere absence of a positive recitation is not basis for an exclusion. See *Ex parte Grasselli*, 231 USPQ 393 (Bd. App. 1983), *aff'd mem.*, 738 F.2d 453 (Fed. Cir. 1984).

Applicant is required to cancel the new matter in the reply to this Office Action.

Claim Objections

Claims 21 and 22 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. The claims fail to further limit claim 20 because the

Claim Rejections - 35 USC § 102

ranges in the claims fall between the range given in the parent claim.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Art Unit: 1648

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 7-13, 15, 16, 18, and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Wakenell et al. (American Journal of Veterinary Research. 1986. Vol. 47, pages 933-938.) for reasons of record.

Applicant argues that Wakenell et al. does not teach a vaccine which has not been serially passaged. Applicant is arguing new limitations introduced into the claims that are not supported by the original disclosure. Therefore, the rejection is maintained.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 2-6, 14, 17, 20-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wakenell et al. for reasons of record.

Applicant argues that the reference teaches away from the claimed invention and quotes a specific passage from the reference as support for the argument and states that the vaccine taught by Wakenell et al. does not teach the same vaccine development.

Applicant did not give a citation so that the quoted passage could be immediately identified and reviewed. For the record, the passage is found in the paragraph bridging pages 934-935. Furthermore, it appears that applicant is not arguing the reasons set forth in the original §103 rejection and is arguing why the reference does not anticipate the invention. However,

Art Unit: 1648

after reviewing the reference, the arguments presented have not been found convincing because the passage quoted by applicant is taken out of context. Maternal-antibody-positive chicks hatching from eggs injected with P₄₀-IBV developed antibodies to IBV and were protected against challenge upon exposure to virulent Massachusetts strain 41 IBV at 4 weeks of age. See the abstract, materials and methods section on pages 933-934. A non-serially passaged vaccine introduced by the amendment is new matter which is not conveyed by the original specification. The rejection is maintained.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this

final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shanon A. Foley whose telephone number is (703) 308-3983. The examiner can normally be reached on 7:30-4:30 M-F.

Art Unit: 1648

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on (703) 308-4027. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4426 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Shanon Foley/SAF September 12, 2001

JAMES HOUSEL 929/0 SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600